$BRTX News

Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms Undisclosed

BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Presents Data Showing MSC-Derived Exosomes Have Source-Specific Functional Signatures For Targeted Therapeutic Applications At The International Society For Cell & Gene Therapy 2026 Annual Meeting

BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update

BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform

BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform

BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform

BioRestorative Therapies Announces Strategic Collaboration With 203 Creates To Commercialize BioRestorative's Biocosmeceutical Platform

BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales

BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate

BioRestorative Therapies To Present Data On ~45 Participants From Its Phase 2 Clinical Study Of Hypoxic-cultured Mesenchymal Stem Cells To Treat Chronic Lumbar Disc Disease

Curious about the most active stocks on Tuesday?

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

BioRestorative Therapies shares are trading higher after the company announced that IP Australia allowed Patent Application No. 2020265664 titled "Non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates, and methods of generating and using the same."

BioRestorative Therapies Secures Australian Patent Allowance For 3D Brown Adipose-Derived Stem Cell Aggregates

Unusual volume stocks are being observed in Monday's session.

Unusual volume stocks are being observed in Wednesday's session.

Which stocks have an unusual volume on Tuesday?

BioRestorative Announces Closing of $5.0 Million Public Offering

12 Health Care Stocks Moving In Friday's After-Market Session